We work according to GMP and ISO standards from pre-clinical through clinical trial phases to scale up, validation and commercial manufacturing. Out Quality Control team is experienced and they make sure that the products are manufactured to the correct specifications within the Marketing Authorization (MA) or Clinical Trial Dossier (CTD). We have been successfully inspected by the FDA and our facility is regularly routinely inspected by the Swedish Medicines Agency.
Magle AB (formed in 1995 as a pure development company) acquired Chemoswed AB (formed in 1944 as a manufacturing company) in 2016 before merging the companies in 2017 to form Magle Chemoswed. In 2019, Adroit Science AB was acquired to increase the development services segment. In 2021, PharmaCept GmbH was acquired as a first step to develop a sales and marketing organization for DSM products. Most recent to join the Magle Group is Magle Biopolymers - a CDMO part of the group focusing on Dextran technology.
Let’s recruit together and find your next colleague.
